fbpx

COVID-19 Vaccine Eligibility Guide

Facebook
Twitter
LinkedIn
Print

This guide contains information to help individuals determine their eligibility for COVID-19 vaccine and vaccine booster shots. This guide is updated regularly as vaccine eligibility guidelines change. Use the tabs below to determine your eligibility for the COVID-19 vaccine.

For additional information about COVID-19 vaccine and booster eligibility, review the CDC’s vaccination guide here. Individuals with compromised immune systems have separate vaccine and booster eligibility criteria, which can be found here.

If you are interested in getting vaccinated against COVID-19, use the button below to find a vaccination site near you:

Primary Vaccination Series

Infants and Children 6 Months-4 Years

Eligible to receive a COVID-19 Vaccine manufactured by Pfizer-BioNTech or Moderna.

Children 5-11 Years

Eligible to receive a COVID-19 Vaccine manufactured by Pfizer-BioNTech or Moderna.

Young Adults 12-15 Years

Eligible to receive a COVID-19 vaccine manufactured by Pfizer-BioNTech, Moderna, or Novavax.

Young Adults 16-17 Years

Eligible to receive a COVID-19 vaccine manufactured by Pfizer-BioNTech, Moderna, or Novavax.

Adults 18-64 Years

Eligible to receive a COVID-19 vaccine manufactured by Johnson & Johnson, Moderna, Novavax, or Pfizer-BioNTech.

Adults 65+ Years

Eligible to receive a COVID-19 vaccine manufactured by Johnson & Johnson, Moderna, Novavax, or Pfizer-BioNTech.

First Booster Dose

Children 6 Months-4 Years (Pfizer-BioNTech)

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Pfizer-BioNTech at least two months after completion of the primary vaccination series.

Children 5-11 Years (Pfizer-BioNTech)

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Pfizer-BioNTech at least two months after completion of the primary vaccination series.

Children 6 Months-5 Years (Moderna)

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Moderna at least two months after completion of the primary vaccination series.

Children 6-11 Years (Moderna)

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Moderna at least two months after completion of the primary vaccination series.

Young Adults 12-17 Years

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Moderna or Pfizer-BioNTech at least two months after completion of the primary vaccination series.

Adults 18-65+ Years

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Moderna or Pfizer-BioNTech at least two months after completion of the primary vaccination series.

Eligible to receive a COVID-19 vaccine booster manufactured by Novavax at least six months after completion of the primary vaccination series.

Second Booster Dose

Children 5-11 Years (Pfizer-BioNTech)

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Pfizer-BioNTech at least two months after receiving the first booster dose.

Children 6-11 Years (Moderna)

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Moderna at least two months after receiving the first booster dose.

Young Adults 12-17 Years

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Moderna or Pfizer-BioNTech at least two months after receiving the first booster dose.

Adults 18-49 Years

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Pfizer-BioNTech or Moderna at least two months after receiving the first booster dose.

Adults 50+ Years

Eligible to receive a bivalent COVID-19 vaccine booster manufactured by Moderna or Pfizer-BioNTech at least two months after receiving the first booster dose.

Notes and Sources

Notes

  • The availability of these vaccines and vaccine boosters may be subject to Emergency Use Authorization, which is a status granted by the U.S. Food and Drug Administration (FDA) that authorizes unapproved medical products or unapproved uses of approved medical products to be used during emergencies. These medical products are temporarily authorized to diagnose, treat, or prevent life-threatening diseases when there are no available alternatives.

  • On May 5, 2022, the U.S. FDA limited the use of the Johnson & Johnson/Janssen COVID-19 Vaccine to (1) individuals 18 years of age and older who are unable to obtain an alternative COVID-19 vaccine due to a lack of accessibility or clinical appropriateness and (2) individuals 18 years of age and older who elect to receive the Johnson & Johnson/Janssen COVID-19 Vaccine because they would not otherwise receive a COVID-19 vaccine.

  • Authorized on August 31, 2022, “bivalent” COVID-19 vaccines contain components that protect broadly against COVID-19 and the BA.4 and BA.5 lineages of the omicron variant. Monovalent COVID-19 vaccine boosters will no longer be available for individuals 12 years of age and older.
  • A list of underlying health conditions that place an individual at high-risk for severe COVID-19 can be found here.

  • Pandemic Patients recommends consulting with your health care provider to discuss getting vaccinated against COVID-19.

  • This page was last updated on 12/15/2022.

Sources

“Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals,” U.S. Food and Drug Administration, August 12, 2021, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised.

“FDA Approves First COVID-19 Vaccine,” U.S. Food and Drug Administration, August 23, 2021, https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.

“People with Certain Medical Conditions,” U.S. Centers for Disease Control and Prevention, Updated on October 14, 2021, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.

“Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines,” U.S. Food and Drug Administration, October 20, 2021, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines.

“Moderna COVID-19 Vaccine,” U.S. Food and Drug Administration, Updated on October 20, 2021, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine.

“Janssen COVID-19 Vaccine,” U.S. Food and Drug Administration, Updated on October 22, 2021, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine.

“Comirnaty and Pfizer-BioNTech COVID-19 Vaccine,” U.S. Food and Drug Administration, Updated on October 26, 2021, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine.

“Spikevax and Moderna COVID-19 Vaccine,” U.S. Food and Drug Administration, Updated on 2/23/2022, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine.

“FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age,” U.S. Food and Drug Administration, October 29, 2021, https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.

“Emergency Use Authorization,” U.S. Food and Drug Administration, Updated on October 29, 2021, https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.

“Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters,” U.S. Food and Drug Administration, November 19, 2021, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters.

“Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds,” U.S. Food and Drug Administration, December 9, 2021, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-booster-dose-16-and-17.

“Coronavirus (COVID-19) Update: FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine,” U.S. Food and Drug Administration, January 3, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-multiple-actions-expand-use-pfizer-biontech-covid-19-vaccine.

“Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months,” U.S. Food and Drug Administration, January 7, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-shortens-interval-booster-dose-moderna-covid-19-vaccine-five-months.

“Coronavirus (COVID-19) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine,” U.S. Food and Drug Administration, January 31, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-key-action-approving-second-covid-19-vaccine.

“Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals,” U.S. Food and Drug Administration, March 29, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and.

“Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals,” U.S. Food and Drug Administration, May 5, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals.

“Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age,” U.S. Food and Drug Administration, June 17, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children.

“Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted,” U.S. Food and Drug Administration, July 13, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted.

“FDA Roundup: August 19, 2022,” U.S. Food and Drug Administration, August 19, 2022, https://www.fda.gov/news-events/press-announcements/fda-roundup-august-19-2022.

“Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose,” U.S. Food and Drug Administration, August 31, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use.

“Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups,” U.S. Food and Drug Administration, October 12, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-bivalent-covid-19-vaccines.

“Emergency Use Authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted to prevent Coronavirus Disease 2019 (COVID-19),” U.S. Food and Drug Administration, October 19, 2022, https://www.fda.gov/media/159897/download.

“Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age,” U.S. Food and Drug Administration, December 8, 2022, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-updated-bivalent-covid-19-vaccines-children-down-6-months.